{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:30:30Z","timestamp":1787783430829,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejso.2026.111453","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:44:32Z","timestamp":1769701472000},"page":"111453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Integrating molecular classification into endometrial cancer management"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8373-8569","authenticated-orcid":false,"given":"Giorgio","family":"Bogani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3210-9102","authenticated-orcid":false,"given":"Amy","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5501-1936","authenticated-orcid":false,"given":"Giuseppe","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fanfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica N.","family":"McAlpine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2026.111453_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejso.2026.111453_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2026.111453_bib3","doi-asserted-by":"crossref","DOI":"10.1097\/AOG.0000000000006080","article-title":"Molecular characterization and clinical implications of endometrial cancer","author":"Secord","year":"2025","journal-title":"Obstet Gynecol"},{"issue":"7447","key":"10.1016\/j.ejso.2026.111453_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejso.2026.111453_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"issue":"16","key":"10.1016\/j.ejso.2026.111453_bib6","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2026.111453_bib7","series-title":"Female genital tumours: WHO classification of tumours","year":"2020"},{"issue":"7","key":"10.1016\/j.ejso.2026.111453_bib8","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2026.111453_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100085","article-title":"Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.ejso.2026.111453_bib10","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2026.111453_bib11","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(25)00379-1","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial","volume":"26","author":"Post","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.111453_bib12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejso.2026.111453_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"10.1016\/j.ejso.2026.111453_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/ijgc-2022-004039","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program","volume":"33","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"16","key":"10.1016\/j.ejso.2026.111453_bib15","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejso.2026.111453_bib16","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","article-title":"Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study","volume":"29","author":"Oaknin","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.ejso.2026.111453_bib17","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejso.2026.111453_bib18","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ejso.2026.111453_bib22","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/cncr.33516","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis","volume":"127","author":"McAlpine","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejso.2026.111453_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.ejso.2026.111453_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100423","article-title":"Molecular and clinicopathologic characterization of mismatch repair-deficient endometrial carcinoma not related to MLH1 promoter hypermethylation","volume":"37","author":"Kaya","year":"2024","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.ejso.2026.111453_bib25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.5375","article-title":"p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies","volume":"250","author":"Singh","year":"2020","journal-title":"J Pathol"},{"issue":"12","key":"10.1016\/j.ejso.2026.111453_bib26","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1136\/ijgc-2024-005916","article-title":"Validation and clinical performance of a single test, DNA based endometrial cancer molecular classifier","volume":"34","author":"Jamieson","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2026.111453_bib27","article-title":"Relationship between abnormal p53 expression and high-risk histology in endometrial cancers and living in proximity to hog concentrated animal feeding operations in North Carolina","volume":"60","author":"Boissiere","year":"2025","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.ejso.2026.111453_bib28","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ygyno.2023.01.025","article-title":"Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer","volume":"170","author":"Jamieson","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2026.111453_bib29","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/PGP.0000000000001120","volume":"44","author":"Huvila","year":"2025","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ejso.2026.111453_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2025.05.015","article-title":"Prognostic significance of estrogen receptor expression and estrogen signaling in endometrial carcinomas of no specific molecular profile: a comprehensive molecular and pathologic analysis","volume":"198","author":"Lam","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.111453_bib31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"issue":"12","key":"10.1016\/j.ejso.2026.111453_bib34","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","article-title":"PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer","volume":"30","author":"van den Heerik","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ejso.2026.111453_bib36","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ejso.2026.111453_bib32","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-23-1397","article-title":"Clinical behavior and molecular landscape of stage I p53-Abnormal low-grade endometrioid endometrial carcinomas","volume":"29","author":"Jamieson","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejso.2026.111453_bib33","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1158\/1078-0432.CCR-23-3689","article-title":"Targeted and shallow whole-genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers","volume":"30","author":"Jamieson","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejso.2026.111453_bib37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2026.111453_bib38","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.annonc.2024.08.2242","article-title":"ENGOT-en11\/GOG-3053\/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","volume":"35","author":"Van Gorp","year":"2024","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.ejso.2026.111453_bib39","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3390\/cells14161282","article-title":"HER2\/neu as a signaling and therapeutic marker in uterine serous carcinoma","volume":"14","author":"Ettorre","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.ejso.2026.111453_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2025.07.024","article-title":"HER2 expression in an endometrial cancer cohort","volume":"201","author":"Hacker","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111453_bib41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2026.111453_bib42","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1016\/S1470-2045(24)00192-X","article-title":"Clinical research in endometrial cancer: consensus recommendations from the gynecologic cancer InterGroup","volume":"25","author":"Creutzberg","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.111453_bib43","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1002\/cncr.34328","article-title":"Molecular classification in endometrial cancer: opportunities for precision oncology in a changing landscape","volume":"128","author":"Jamieson","year":"2022","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ejso.2026.111453_bib44","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/14737140.2025.2522948","article-title":"An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma","volume":"25","author":"Coleman","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1016\/j.ejso.2026.111453_bib45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1535-7163.MCT-22-0322","article-title":"Discovery of STRO-002, a novel homogeneous ADC targeting folate receptor alpha, for the treatment of ovarian and endometrial cancers","volume":"22","author":"Li","year":"2023","journal-title":"Mol Cancer Therapeut"},{"issue":"10","key":"10.1016\/j.ejso.2026.111453_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102035","article-title":"Fertility-sparing approach in endometrioid grade II endometrial cancer: the role of molecular classification","volume":"35","author":"Bogani","year":"2025","journal-title":"Int J Gynecol Cancer"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326000727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326000727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T11:37:32Z","timestamp":1774697852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326000727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0748798326000727"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111453","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating molecular classification into endometrial cancer management","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111453"}}